ArticleJournal of vascular and interventional radiology : JVIR2025
Breast Cancer Recurrence after Cryoablation in Patients Who Are Poor Surgical Candidates or Who Refuse Surgery.
Article in Journal of vascular and interventional radiology : JVIR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Tolerability of breast radiotherapy following cryoablation in the local management or palliation of breast cancer: a case series.Annals of medicine and surgery (2012) · 2026Article
- Cryoablation in Early-Stage Breast Cancer: A Systematic Review of Efficacy, Safety and Oncologic Outcomes.Cancers · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo evaluate in-breast recurrence rates after cryoablation in patients with primary breast cancer who were poor surgical candidates or refused surgery. MATERIALS AND
methodsPatients with primary breast cancer who were poor surgical candidates or who refused surgery and were treated with cryoablation at a single academic cancer center between October 2018 and June 2023 were retrospectively reviewed. Of the 60 treated patients, 45 had invasive ductal carcinoma, 6 had invasive lobular carcinoma, 2 had multicentric ductal carcinoma in situ, and 7 had other histology. Tumor size ranged from 0.3 to 9 cm, with a mean of 2.7 cm. Recurrence was defined as new tumor or regrowth of residual tumor in the ipsilateral breast.
resultsWith a mean follow-up of 21 months and median follow-up of 9.8 months, there was a recurrence rate of 10% (6 of 60 patients). Patients in the recurrence group had more poorly differentiated disease than those in the nonrecurrence group (66.7% vs 22.2%; P = .038). Tumor size did not differ between nonrecurrence and recurrence groups (nonrecurrence group mean, 2.7 cm [SD ± 2.6]; recurrence group mean, 2.5 cm [SD ± 1.0]; P = .506). Patients who were treated with palliative intent rather than curative intent were significantly older (79.7 years [SD ± 12.2] vs 72.5 years [SD ± 11.3]; P = .032).
conclusionsCryoablation can be considered a treatment option in patients who are poor surgical candidates or who refuse surgery, with a 10% recurrence rate at a mean follow-up of 21 months in this retrospective review that included patients with tumors up to 9 cm, unfavorable pathology, and multicentric disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.